✦ LIBER ✦

ND2 MODELING THE COST-EFFECTIVENESS OF A NEW TREATMENT FOR MS (NATALIZUMAB) COMPARED TO CURRENT STANDARD PRACTICE IN SWEDEN

✍ Scribed by G Kobelt; J Berg; P Lindgren; J Hillert

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PMS54 COST-EFFECTIVENESS OF TOCILIZUMAB

✍ Diamantopoulos, A; Wintfeld, N; Giuliani, G 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

PMS30 Cost-Effectiveness of Tocilizumab

✍ A. Diamantopoulos; S. Andrade; A. Bernardo; J. Branco; L. Inês; J.A. Pereira da 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

ECONOMIC MODELING OF COST-EFFECTIVENESS

✍ Turco, Mark A.; Cannon, Louis A.; Amorosi, Stacey L.; Stern, Sean; Stivland, Tim 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 284 KB

PES2 A DECISION-ANALYTIC MODEL TO COMPAR

✍ M Aristides; D Tilden; P Robinson; A Weston; P Davey; G Aldridge 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB